RYTM Rhythm Pharmaceuticals Inc
Price (delayed)
$51.96
Market cap
$3.29B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.34
Enterprise value
$3.2B
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within
Highlights
The gross profit has soared by 71% YoY and by 17% from the previous quarter
RYTM's revenue has soared by 68% YoY and by 16% QoQ
Rhythm Pharmaceuticals's equity has soared by 94% from the previous quarter but it has plunged by 87% YoY
The quick ratio has declined by 44% year-on-year and by 10% since the previous quarter
RYTM's net income is down by 41% year-on-year
Key stats
What are the main financial stats of RYTM
Market
Valuations
Earnings
Shares outstanding
63.22M
Market cap
$3.29B
Enterprise value
$3.2B
Price to earnings (P/E)
N/A
Price to book (P/B)
146.96
Price to sales (P/S)
24.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.59
Revenue
$130.13M
Gross profit
$116.76M
Operating income
-$265.5M
Net income
-$260.6M
EBIT
-$239.65M
EBITDA
-$238.09M
Free cash flow
-$113.88M
Per share
Balance sheet
Liquidity
EPS
-$4.34
EPS diluted
-$4.34
Free cash flow per share
-$1.87
Book value per share
$0.35
Revenue per share
$2.13
TBVPS
$6.33
Total assets
$392.27M
Total liabilities
$227.72M
Debt
$3.94M
Equity
$21.73M
Working capital
$258.68M
Debt to equity
0.18
Current ratio
3.24
Quick ratio
2.94
Net debt/EBITDA
0.36
Margins
Efficiency
Dividend
EBITDA margin
-183%
Gross margin
89.7%
Net margin
-200.3%
Operating margin
-204%
Return on assets
-75.8%
Return on equity
-790.5%
Return on invested capital
-135.4%
Return on capital employed
-86.6%
Return on sales
-184.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RYTM stock price
How has the Rhythm Pharmaceuticals stock price performed over time
Intraday
3.92%
1 week
-4.31%
1 month
-5.37%
1 year
29.74%
YTD
-7.18%
QTD
-1.91%
Financial performance
How have Rhythm Pharmaceuticals's revenue and profit performed over time
Revenue
$130.13M
Gross profit
$116.76M
Operating income
-$265.5M
Net income
-$260.6M
Gross margin
89.7%
Net margin
-200.3%
The gross profit has soared by 71% YoY and by 17% from the previous quarter
RYTM's revenue has soared by 68% YoY and by 16% QoQ
Rhythm Pharmaceuticals's operating income has decreased by 44% YoY
RYTM's net income is down by 41% year-on-year
Growth
What is Rhythm Pharmaceuticals's growth rate over time
Valuation
What is Rhythm Pharmaceuticals stock price valuation
P/E
N/A
P/B
146.96
P/S
24.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.59
The EPS has contracted by 36% YoY
Rhythm Pharmaceuticals's equity has soared by 94% from the previous quarter but it has plunged by 87% YoY
RYTM's P/B is 2.9% above its last 4 quarters average of 137.5
RYTM's price to sales (P/S) is 99% lower than its 5-year quarterly average of 2079.7 and 13% lower than its last 4 quarters average of 26.9
RYTM's revenue has soared by 68% YoY and by 16% QoQ
Efficiency
How efficient is Rhythm Pharmaceuticals business performance
The ROE has plunged by 113% from the previous quarter
Rhythm Pharmaceuticals's return on invested capital has shrunk by 53% YoY and by 4% QoQ
The ROA has contracted by 38% YoY but it has grown by 3.2% from the previous quarter
The ROS has grown by 16% YoY and by 13% from the previous quarter
Dividends
What is RYTM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RYTM.
Financial health
How did Rhythm Pharmaceuticals financials performed over time
The total assets is 72% more than the total liabilities
The quick ratio has declined by 44% year-on-year and by 10% since the previous quarter
Rhythm Pharmaceuticals's current ratio has decreased by 42% YoY and by 7% from the previous quarter
The debt is 82% smaller than the equity
Rhythm Pharmaceuticals's equity has soared by 94% from the previous quarter but it has plunged by 87% YoY
The debt to equity has dropped by 50% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.